Thermo Fisher Scientific (TMO) is back in the spotlight after using the BIO International 2026 convention in San Diego to showcase AI driven research tools and integrated drug development workflows for pharma and biotech clients.

Thermo Fisher Scientific’s recent AI focus at BIO International comes after a mixed stretch for the stock, with the share price down 20.79% year to date but a 1 year total shareholder return of 16.49% signaling improving sentiment over a longer horizon.

If you are comparing Thermo Fisher Scientific with other AI driven healthcare opportunities, it can be useful to scan a wider field of potential candidates through 38 healthcare AI stocks

With Thermo Fisher Scientific down 20.79% year to date, yet showing a 16.49% 1-year total return and trading below some intrinsic and analyst value estimates, is this a reset that creates a potential entry point, or is the market already pricing in future growth?

Most Popular Narrative: 23.3% Undervalued

Compared with Thermo Fisher Scientific's last close at $469.35, the most followed narrative points to a fair value of $611.56, putting a spotlight on how future growth and profitability are being modeled.

The analysts have a consensus price target of $611.56 for Thermo Fisher Scientific based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $750.0, and the most bearish reporting a price target of just $490.0.

Want to see what sits behind that valuation gap? The narrative leans on steady revenue expansion, rising profit margins and a richer earnings multiple. Curious which assumptions really move the fair value needle? The full story lays out the numbers that have analysts projecting a higher long term earnings base.

Result: Fair Value of $611.56 (UNDERVALUED)

However, Thermo Fisher Scientific still faces pressure from weaker academic and government demand, as well as ongoing China and tariff related headwinds that could challenge those upbeat earnings assumptions.

Next Steps

With Thermo Fisher Scientific balancing both enthusiasm and concern in this narrative, it makes sense to move quickly, review the details, and weigh the 5 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Thermo Fisher Scientific?

If Thermo Fisher Scientific has you thinking about what else might belong on your radar, now is the time to widen your search and stress test your watchlist.

• Spot potential high growth opportunities earlier by scanning 24 elite penny stocks with strong financials, which already show stronger financial footing than many peers.
• Zero in on quality at a reasonable price by reviewing the 44 high quality undervalued stocks, which combine solid fundamentals with attractive valuation metrics.
• Strengthen your core holdings by filtering for companies in the solid balance sheet and fundamentals stocks screener (48 results), which pair resilience with dependable financial structures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.